Featured Research

from universities, journals, and other organizations

Large increase seen in number of lymph nodes evaluated for colon cancer, but no corresponding rise in node-positive cancers

Date:
September 14, 2011
Source:
JAMA and Archives Journals
Summary:
During the past two decades there has been a significant increase in the percentage of patients who have a high number of lymph nodes evaluated during colon cancer operations, but this improvement is not associated with an increase in the overall proportion of colon cancers that are node positive, according to a new study.

During the past two decades there has been a significant increase in the percentage of patients who have a high number of lymph nodes evaluated during colon cancer operations, but this improvement is not associated with an increase in the overall proportion of colon cancers that are node positive, according to a study in the September 14 issue of JAMA.

"As wide-ranging quality improvement efforts emerge throughout the health care system, finding mechanisms for optimizing cancer care through accurate staging and appropriate treatment has become an area of substantial interest to policy makers. Among patients surgically treated for colon cancer, several studies have demonstrated better survival for patients with more lymph nodes evaluated," according to background information in the article. "The proposed mechanism behind this association suggests that a more extensive lymph node evaluation reduces the risk of understaging, in which inadequate assessment may incorrectly identify a patient with node-positive disease as node negative, thus failing to identify appropriate treatment."

Most practice organizations and consensus panels now advocate for the surgical evaluation of 12 or more lymph nodes for acceptable staging of newly diagnosed colon cancer patients. "Recently, some studies have questioned the understaging mechanism, suggesting that efforts by payers and professional associations to increase the number of lymph nodes evaluated during colon cancer surgery may have a limited role in improving survival," the authors write.

Helen M. Parsons, M.P.H., of the National Cancer Institute, Bethesda, Md., and colleagues examined trends in the degree of lymph node evaluation for colon cancer and how they are associated with survival. The researchers analyzed data from the Surveillance, Epidemiology, and End Results (SEER) program, from 1988 through 2008. Included in the analysis were 86,394 patients surgically treated for colon cancer.

The researchers found that lymph node evaluation for colon cancer increased markedly from 1988 to 2008. During 1988-1990, 34.6 percent of patients (n = 3,875) received lymph node evaluation at a level of 12 lymph nodes or more. By 1994-1996, 37.9 percent of patients (n = 4,362) had an evaluation at this level, with this percentage increasing to 46.8 percent in 2000-2002 and 73.6 percent (9,798/13,310) in 2006-2008. Even though the number of lymph nodes evaluated increased significantly, this change was not associated with an increase in node-positive cancers over this period (40 percent in 1988-1990, 42 percent in 2006-2008).

The authors also found that although patients with high rates of lymph node evaluation were only slightly more likely to have node-positive disease, these patients experienced significantly lower relative hazard of 5-year death compared with those with fewer nodes evaluated. "When stratified by node positivity, patients with node-positive disease as well as node-negative disease continued to experience lower relative hazard of death when more lymph nodes were evaluated."

"In conclusion, the number of lymph nodes evaluated for colon cancer markedly increased in the past 2 decades but was not associated with an overall shift toward higher-staged cancers, questioning the upstaging mechanism as the primary basis for improved survival in patients with more lymph nodes evaluated."

Editorial: Lymph Node Evaluation in Colon Cancer -- Assessing the Link Between Quality Indicators and Quality

Sandra L. Wong, M.D., M.S., of the University of Michigan, Ann Arbor, Mich., writes in an accompanying editorial that the findings of this study indicate that the use of some quality indicators is questionable.

"One of the major hazards associated with the development and implementation of quality indicators is the lack of association with outcomes because the mechanisms by which adherence to certain processes of care lead to improved outcomes are unclear. What is clear, however, is that seemingly straightforward associations between processes of care and improvements in outcomes are not easily understood and these relationships may not be causal. The quality indicator of counting more than 12 lymph nodes per resected colon cancer specimen does not directly measure a process that by itself improves outcomes. The study by Parsons et al further questions the utility of this indicator."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal References:

  1. H. M. Parsons, T. M. Tuttle, K. M. Kuntz, J. W. Begun, P. M. McGovern, B. A. Virnig. Association Between Lymph Node Evaluation for Colon Cancer and Node Positivity Over the Past 20 Years. JAMA: The Journal of the American Medical Association, 2011; 306 (10): 1089 DOI: 10.1001/jama.2011.1285
  2. S. L. Wong. Lymph Node Evaluation in Colon Cancer: Assessing the Link Between Quality Indicators and Quality. JAMA: The Journal of the American Medical Association, 2011; 306 (10): 1139 DOI: 10.1001/jama.2011.1318

Cite This Page:

JAMA and Archives Journals. "Large increase seen in number of lymph nodes evaluated for colon cancer, but no corresponding rise in node-positive cancers." ScienceDaily. ScienceDaily, 14 September 2011. <www.sciencedaily.com/releases/2011/09/110913161943.htm>.
JAMA and Archives Journals. (2011, September 14). Large increase seen in number of lymph nodes evaluated for colon cancer, but no corresponding rise in node-positive cancers. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/09/110913161943.htm
JAMA and Archives Journals. "Large increase seen in number of lymph nodes evaluated for colon cancer, but no corresponding rise in node-positive cancers." ScienceDaily. www.sciencedaily.com/releases/2011/09/110913161943.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins